Get the Stockscreener App
15.56
2.03%
0.31
Prothena Corporation Plc stock is traded at $15.56, with a volume of 724.17K.
It is up +2.03% in the last 24 hours and up +10.28% over the past month.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
See More
Previous Close:
$15.25
Open:
$15.91
24h Volume:
724.17K
Relative Volume:
1.46
Market Cap:
$836.69M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-15.56
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+9.81%
1M Performance:
+10.28%
6M Performance:
-29.14%
1Y Performance:
-42.48%
1-Day Range:
$14.77
$16.66
1-Week Range:
$13.69
$16.66
52-Week Range:
$11.70
$31.03
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
15.56 | 836.69M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think - Simply Wall St
Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Call Transcript - Insider Monkey
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus - Yahoo Finance
RBC Cuts Price Target on Prothena to $20 From $24, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Prothena Corporation (NASDAQ: PRTA) Gears Up for Transformational 2025 with Key Clinical Milestones - Pradesh Tak
Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ... - Yahoo Finance
Earnings call transcript: Prothena's Q4 2024 results highlight innovation - Investing.com
Earnings call transcript: Prothena’s Q4 2024 results highlight innovation By Investing.com - Investing.com Nigeria
Prothena: Q4 Earnings Snapshot -February 20, 2025 at 04:23 pm EST - Marketscreener.com
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire
(PRTA) Trading Advice - Stock Traders Daily
Prothena Corporation PLC expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm - EIN News
The Prothena Corporation plc (PRTA) had a good session last reading, didn’t it? - US Post News
Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 - Business Wire
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Focused Wealth Management Inc Makes New Investment in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Critical Survey: Prothena (NASDAQ:PRTA) vs. Annexon (NASDAQ:ANNX) - Defense World
Prothena (PRTA) to Release Quarterly Earnings on Thursday - Defense World
Prothena (NASDAQ:PRTA) Given New $62.00 Price Target at Oppenheimer - MarketBeat
KALA BIO (NASDAQ:KALA) and Prothena (NASDAQ:PRTA) Financial Survey - Defense World
Prothena (NASDAQ:PRTA) Price Target Raised to $62.00 - Defense World
Form S-8Securities to be offered to employees in employee benefit plans - br.ADVFN.com
Learn to Evaluate (PRTA) using the Charts - Stock Traders Daily
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings) - Benzinga
Metric Analysis: Prothena Corporation plc (PRTA)’s Key Ratios in the Limelight - The Dwinnex
Further weakness as Prothena (NASDAQ:PRTA) drops 16% this week, taking three-year losses to 61% - Yahoo Finance
Q2 Earnings Forecast for Prothena Issued By Zacks Research - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Down 4.8%Here's What Happened - MarketBeat
SG Americas Securities LLC Increases Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Equities Analysts Offer Predictions for Prothena Q2 Earnings - Defense World
Brokerages Set Prothena Co. plc (NASDAQ:PRTA) Price Target at $46.50 - Defense World
Duncan Williams Asset Management LLC Has $958,000 Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $46.50 Consensus PT from Brokerages - MarketBeat
Prothena (NASDAQ:PRTA) Trading 6.7% HigherHere's Why - MarketBeat
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price - Simply Wall St
Cantor Fitzgerald Predicts Prothena FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Prothena FY2025 Earnings - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
JPMorgan Chase & Co. Has $3.35 Million Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Hennion & Walsh Asset Management Inc. Takes $724,000 Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Shares Up 6.8%Time to Buy? - MarketBeat
Trading (PRTA) With Integrated Risk Controls - Stock Traders Daily
AL Amyloidosis Pipeline Analysis 2024: FDA Approvals, Emerging - openPR
Barclays PLC Grows Stock Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Purchased by Barclays PLC - Defense World
Prothena (NASDAQ:PRTA) Stock Price Down 9%Here's What Happened - MarketBeat
Prothena (NASDAQ:PRTA) Trading Up 6.5%What's Next? - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $52.29 Average Price Target from Analysts - Defense World
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):